Development of PI3K inhibitors: lessons learned from early clinical trials
Vall d'Hebron Institut de Recerca · Hebron University · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
765
total citations
- FWCI
- 47.27
- Percentile
- 100%
- References
- 114
Citations per year
Authors
4- JRJordi RodónCorresponding
Vall d'Hebron Institut de Recerca, Hebron University, Universitat Autònoma de Barcelona
- RDRodrigo Dienstmann
Vall d'Hebron Institut de Recerca, Vall d'Hebron Institute of Oncology
- VSVioleta Serra
Vall d'Hebron Institut de Recerca, Vall d'Hebron Institute of Oncology
- JTJosep Tabernero
Universitat Autònoma de Barcelona
Topics & keywords
Topics
Keywords
- PI3K/AKT/mTOR pathway
- Clinical trial
- Medicine
- Drug development
- Protein kinase B
- Biomarker
- Translational research
- Bioinformatics
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.